Methocarbamol
Brand names: Methocarbamol
At a glance
- Medicare prescriptions, 2024
- 2,377,500
- Medicare drug cost
- $28.1M
- Average cost per prescription
- $11.81
- Clinicians who prescribed it
- 74,809
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Methocarbamol Tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nurse Practitioners 24.8%
- Family Medicine 19.5%
- Physician Assistants 14.6%
- Internal Medicine 12.7%
- Pain Medicine 9.3%
- Emergency Medicine 3.2%
- Physical Medicine & Rehabilitation (PM&R) 2.8%
- Orthopedic Surgery 2.6%
- Neurosurgery 1.6%
- Anesthesiology 1.1%
- Neurology 1.0%
- Spine Surgery 0.9%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 234% from 2019 to 2024.
Biggest change by state since 2019
- Florida +357%
- Colorado +332%
- South Carolina +326%
- Texas +299%
- Georgia +296%
- Massachusetts (smallest change) +116%
- Washington (smallest change) +120%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Doc Rx
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white round tablet, 19 mm | 611 O |
Marlex Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white round tablet, 13 mm, scored to split in 2 | G173 |
| 750 mg | white oval tablet, 19 mm | G174 |
Medcore LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white round tablet, 13 mm, scored to split in 2 | G173 |
| 750 mg | white oval tablet, 19 mm | G174 |
Nucare Pharmaceuticals,inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | orange round tablet, 13 mm, scored to split in 2 | G 500 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white round tablet, 13 mm, scored to split in 2 | G173 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $128,370 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Forte Bio-pharma LLC $128,370
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Mar 2025 · Somerset Therapeutics Private Limited · Class II
Lack of Assurance of Sterility: Media fill with bacterial contamination - Feb 2024 · Eugia US LLC · Class I
Presence of Particulate Matter
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.